Following the success of the tyrosine kinase inhibitor (TKI) imatinib in chronic myeloid leukemia (CML), research focused on targeted therapy strategies for Ph-positive ALL and other ALL subtypes [9â€“13]. Imatinib has since become part of pre- and posttransplant treatment for patients with Ph-positive ALL [13, 14].